-
PDF
- Split View
-
Views
-
Cite
Cite
Alan J Fowler, Michaeline Hebron, Kaluvu Balaraman, Wangke Shi, Alexander A Missner, Jonathan D Greenzaid, Timothy L Chiu, Clementina Ullman, Ethan Weatherdon, Val Duka, Yasar Torres-Yaghi, Fernando L Pagan, Xiaoguang Liu, Habtom Ressom, Jaeil Ahn, Christian Wolf, Charbel Moussa, Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases, Human Molecular Genetics, Volume 30, Issue 13, 1 July 2021, Pages 1271–1272, https://doi.org/10.1093/hmg/ddab082
- Share Icon Share
In the version of this article initially published, there was a clerical error in calculations used for the pharmacokinetics data presented in figure 2 i-k that resulted in an order of magnitude difference. These calculated data have been corrected in the manuscript (highlighted in red) and in figure 2 i-k. These corrections do not alter the overall results or conclusions of the published article.
These data were originally calculated in Microsoft excel where a formula with an order of magnitude error was created and copy-and-pasted across the analysis spreadsheet, affecting each group in the analysis and resulting in the concentration pharmacokinetics data we reported being an order of magnitude lower than they are. These corrections do not alter the overall results or conclusions which are A. 1.25, 2.5, and 5.0mg/kg BK41043, injected intraperitoneally, is detected in the brain tissue of mice between 1 and 12 hours and B. A maximum concentration of the drug may be reached in the CNS independent of the plasma concentration.
